UBS Knock-Out ABT/ DE000UL98ZN4 /
10/06/2024 13:49:49 | Chg.+0.320 | Bid15:52:14 | Ask15:52:14 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.780EUR | +69.57% | 0.860 Bid Size: 25,000 |
0.870 Ask Size: 25,000 |
Abbott Laboratories | 99.938 USD | 31/12/2078 | Call |
GlobeNewswire
06/06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
09/05
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
25/03
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
15/03
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
14/11/2023
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
19/10/2023
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
10/10/2023
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
02/10/2023
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
GlobeNewswire
06/09/2023
Endexx Corporation Appoints Ahmed Itani to Director of Marketing of HYLA in The Middle East Region